Literature DB >> 28385596

Investigation of aryl isonitrile compounds with potent, broad-spectrum antifungal activity.

Haroon Mohammad1, Kwaku Kyei-Baffour2, Waleed Younis1, Dexter C Davis2, Hassan Eldesouky1, Mohamed N Seleem3, Mingji Dai4.   

Abstract

Invasive fungal infections present a formidable global public health challenge due to the limited number of approved antifungal agents and the emergence of resistance to the frontline treatment options, such as fluconazole. Three fungal pathogens of significant concern are Candida, Cryptococcus, and Aspergillus given their propensity to cause opportunistic infections in immunocompromised individuals. New antifungal agents composed of unique chemical scaffolds are needed to address this public health challenge. The present study examines the structure-activity relationship of a set of aryl isonitrile compounds that possess broad-spectrum antifungal activity primarily against species of Candida and Cryptococcus. The most potent derivatives are capable of inhibiting growth of these key pathogens at concentrations as low as 0.5µM. Remarkably, the most active compounds exhibit an excellent safety profile and are non-toxic to mammalian cells even at concentrations up to 256µM. The present study lays the foundation for further investigation of aryl isonitrile compounds as a new class of antifungal agents.
Copyright © 2017 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Antifungal; Aspergillus; Candida; Cryptococcus; Isonitrile

Mesh:

Substances:

Year:  2017        PMID: 28385596      PMCID: PMC5486875          DOI: 10.1016/j.bmc.2017.03.035

Source DB:  PubMed          Journal:  Bioorg Med Chem        ISSN: 0968-0896            Impact factor:   3.641


  17 in total

Review 1.  Antimicrobial resistance: resistance to antifungal agents: mechanisms and clinical impact.

Authors:  Zeina A Kanafani; John R Perfect
Journal:  Clin Infect Dis       Date:  2008-01-01       Impact factor: 9.079

2.  Antimicrobial ambiguine isonitriles from the cyanobacterium Fischerella ambigua.

Authors:  Shunyan Mo; Aleksej Krunic; George Chlipala; Jimmy Orjala
Journal:  J Nat Prod       Date:  2009-05-22       Impact factor: 4.050

3.  Infectious Disease. How to bolster the antifungal pipeline.

Authors:  David W Denning; Michael J Bromley
Journal:  Science       Date:  2015-03-26       Impact factor: 47.728

Review 4.  Candida species: current epidemiology, pathogenicity, biofilm formation, natural antifungal products and new therapeutic options.

Authors:  J C O Sardi; L Scorzoni; T Bernardi; A M Fusco-Almeida; M J S Mendes Giannini
Journal:  J Med Microbiol       Date:  2012-11-22       Impact factor: 2.472

Review 5.  Antifungal drug development: challenges, unmet clinical needs, and new approaches.

Authors:  Terry Roemer; Damian J Krysan
Journal:  Cold Spring Harb Perspect Med       Date:  2014-05-01       Impact factor: 6.915

6.  Invasive fungal infections among organ transplant recipients: results of the Transplant-Associated Infection Surveillance Network (TRANSNET).

Authors:  Peter G Pappas; Barbara D Alexander; David R Andes; Susan Hadley; Carol A Kauffman; Alison Freifeld; Elias J Anaissie; Lisa M Brumble; Loreen Herwaldt; James Ito; Dimitrios P Kontoyiannis; G Marshall Lyon; Kieren A Marr; Vicki A Morrison; Benjamin J Park; Thomas F Patterson; Trish M Perl; Robert A Oster; Mindy G Schuster; Randall Walker; Thomas J Walsh; Kathleen A Wannemuehler; Tom M Chiller
Journal:  Clin Infect Dis       Date:  2010-04-15       Impact factor: 9.079

7.  The Celecoxib Derivative AR-12 Has Broad-Spectrum Antifungal Activity In Vitro and Improves the Activity of Fluconazole in a Murine Model of Cryptococcosis.

Authors:  Kristy Koselny; Julianne Green; Louis DiDone; Justin P Halterman; Annette W Fothergill; Nathan P Wiederhold; Thomas F Patterson; Melanie T Cushion; Chad Rappelye; Melanie Wellington; Damian J Krysan
Journal:  Antimicrob Agents Chemother       Date:  2016-11-21       Impact factor: 5.191

8.  Secular trends in the epidemiology of nosocomial fungal infections in the United States, 1980-1990. National Nosocomial Infections Surveillance System.

Authors:  C Beck-Sagué; W R Jarvis
Journal:  J Infect Dis       Date:  1993-05       Impact factor: 5.226

Review 9.  Estimation of the current global burden of cryptococcal meningitis among persons living with HIV/AIDS.

Authors:  Benjamin J Park; Kathleen A Wannemuehler; Barbara J Marston; Nelesh Govender; Peter G Pappas; Tom M Chiller
Journal:  AIDS       Date:  2009-02-20       Impact factor: 4.177

10.  Estrogen receptor antagonists are anti-cryptococcal agents that directly bind EF hand proteins and synergize with fluconazole in vivo.

Authors:  Arielle Butts; Kristy Koselny; Yeissa Chabrier-Roselló; Camile P Semighini; Jessica C S Brown; Xuying Wang; Sivakumar Annadurai; Louis DiDone; Julie Tabroff; Wayne E Childers; Magid Abou-Gharbia; Melanie Wellington; Maria E Cardenas; Hiten D Madhani; Joseph Heitman; Damian J Krysan
Journal:  MBio       Date:  2014-02-11       Impact factor: 7.867

View more
  3 in total

1.  Potent Synergistic Interactions between Lopinavir and Azole Antifungal Drugs against Emerging Multidrug-Resistant Candida auris.

Authors:  Hassan E Eldesouky; Ehab A Salama; Nadia A Lanman; Tony R Hazbun; Mohamed N Seleem
Journal:  Antimicrob Agents Chemother       Date:  2020-12-16       Impact factor: 5.191

2.  Natural product-inspired aryl isonitriles as a new class of antimalarial compounds against drug-resistant parasites.

Authors:  Kwaku Kyei-Baffour; Dexter C Davis; Zarko Boskovic; Nobutaka Kato; Mingji Dai
Journal:  Bioorg Med Chem       Date:  2020-08-01       Impact factor: 3.641

3.  Aprepitant, an antiemetic agent, interferes with metal ion homeostasis of Candida auris and displays potent synergistic interactions with azole drugs.

Authors:  Hassan E Eldesouky; Nadia A Lanman; Tony R Hazbun; Mohamed N Seleem
Journal:  Virulence       Date:  2020-12       Impact factor: 5.882

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.